EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex:AIS) announced today that U.S. Patent number 8,021,335 has been granted by United States Patent and Trademark Office (USPTO), covering technology used in the Company’s VIBEX™ platform of needle-assisted jet injection devices. The patent provides protection for the VIBEX technology until 2027. Antares’ VIBEX platform is the basis for several products in development by Antares including VIBEX MTX, the first auto-injector in development to potentially enable rheumatoid arthritis patients to comfortably and safely self-inject methotrexate at home. Antares is a leading U.S. developer of novel and advanced self-injection products including needle-free injectors and pen devices in addition to VIBEX.
